{"gene":"SETD4","run_date":"2026-04-28T20:42:07","timeline":{"discoveries":[{"year":2013,"finding":"SETD4 is a lysine methyltransferase that localizes to both the cytosol and nucleus in breast cancer cells, and its knockdown suppresses proliferation, delays G1/S cell cycle transition, and decreases cyclin D1 expression without affecting apoptosis.","method":"Cell fractionation, confocal immunofluorescence, siRNA knockdown, western blot, flow cytometry","journal":"Journal of cancer science & therapy","confidence":"Medium","confidence_rationale":"Tier 2–3 — clean KD with defined cellular phenotype and molecular readout (cyclin D1), single lab","pmids":["24738023"],"is_preprint":false},{"year":2017,"finding":"SETD4 (Ar-SETD4) catalyzes trimethylation of histone H4K20 (H4K20me3) to promote cell quiescence; knockdown of Ar-SETD4 significantly reduces H4K20me3 levels and prevents quiescent diapause embryo formation in Artemia.","method":"In vitro histone methyltransferase (HMT) assay, overexpression in cell lines, siRNA knockdown, western blot","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro HMT assay confirming enzymatic activity on H4K20, complemented by in vivo knockdown with phenotypic readout","pmids":["28031330"],"is_preprint":false},{"year":2019,"finding":"SETD4 translocates from the cytosol to the nucleus upon LPS stimulation and catalyzes H3K4 monomethylation and dimethylation (H3K4me1/me2) at the TNF-α and IL-6 promoters, thereby positively regulating inflammatory cytokine expression in macrophages downstream of MAPK and NF-κB pathways.","method":"In vitro HMTase assay, SETD4-/- mouse BMDMs, RNA interference, ChIP (H3K4me1/me2 at promoters), immunofluorescence for nuclear translocation","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro HMT assay plus KO macrophages plus ChIP at target gene promoters, multiple orthogonal methods","pmids":["31376731"],"is_preprint":false},{"year":2021,"finding":"Setd4 regulates quiescence of c-Kit+ cardiac progenitor cells via H4K20me3-mediated heterochromatin formation and through the PI3K-Akt-mTOR signaling pathway; conditional knockout of Setd4 causes quiescence exit, increased capillary endothelial cells, and improved cardiac function after myocardial infarction.","method":"Conditional knockout (c-Kit-CreERT2;Setd4f/f mice), lineage tracing (Setd4-Cre;Rosa26mT/mG), immunostaining for H4K20me3, pathway analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO with defined cellular and molecular phenotype in vivo, single lab","pmids":["34079011"],"is_preprint":false},{"year":2021,"finding":"SETD4 knockout in bone marrow mesenchymal stem cells inhibits histone lysine monomethylases and dimethylases and alters genomic DNA methylation at 96,331 CpG sites (affecting promoter regions of genes involved in stem cell biology), impairs migration, myogenic differentiation, and angiogenesis via paracrine VEGF.","method":"CRISPR/Cas9 KO mice, Reduced Representation Bisulfite Sequencing (RRBS), western blot, functional assays (migration, differentiation, angiogenesis)","journal":"Stem cell reviews and reports","confidence":"Medium","confidence_rationale":"Tier 2–3 — CRISPR KO with genome-wide methylation sequencing and functional phenotypes, single lab","pmids":["33506343"],"is_preprint":false},{"year":2022,"finding":"SETD4 methylates the non-histone protein KU70 at lysine 570 (K570); mutations Y272F and Y284F in SETD4 abolish this methylation. Methylated KU70 is enriched in the cytoplasm and suppresses staurosporine-induced apoptosis; the KU70-K570R mutation dampens this anti-apoptotic activity.","method":"Co-IP, in vitro methylation assay, site-directed mutagenesis (SETD4-Y272/284F; KU70-K570R), overexpression/knockdown with apoptosis readout (flow cytometry, cell viability)","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro methylation assay plus mutagenesis of both enzyme and substrate, functional apoptosis readout, multiple orthogonal approaches in one study","pmids":["35545041"],"is_preprint":false},{"year":2022,"finding":"SETD4 epigenetically regulates neural stem cell (NSC) quiescence via H4K20me3-mediated heterochromatin; conditional knockout of Setd4 causes quiescence exit and increased neurogenesis, while overexpression causes quiescence entry and suppressed neurogenesis, demonstrating SETD4 as an epigenetic determinant of deep NSC quiescence.","method":"Conditional knockout, lineage tracing, immunostaining for H4K20me3, overexpression in mice","journal":"Stem cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic KO/OE with defined molecular and phenotypic readouts, single lab","pmids":["36027907"],"is_preprint":false},{"year":2023,"finding":"SETD4 methylates H3K27 to generate H3K27me3 at the NUPR1 promoter, repressing NUPR1 transcription, which subsequently inactivates the Akt signaling pathway and impedes prostate cancer tumorigenesis.","method":"SETD4 knockdown in PCa cells, ChIP for H3K27me3 at NUPR1 promoter, western blot for Akt pathway components","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2–3 — KD plus ChIP demonstrating H3K27me3 at specific promoter with downstream pathway readout, single lab","pmids":["37879429"],"is_preprint":false},{"year":2023,"finding":"Upon viral infection, TBK1-stabilized ZNF268a recruits SETD4 to TBK1, which then catalyzes mono-methylation of TBK1 at lysine 607, critical for assembly of the TBK1 signaling complex and efficient antiviral interferon signaling.","method":"Co-IP (ZNF268a–SETD4–TBK1 interactions), in vitro methylation assay, site-directed mutagenesis, overexpression/knockdown with IFN signaling readout","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro methylation assay identifying TBK1-K607 as substrate, reciprocal co-IP, mutagenesis, functional IFN signaling readout","pmids":["37926288"],"is_preprint":false},{"year":2023,"finding":"SETD4 promotes H4K20me3-mediated heterochromatin formation in quiescent lung cancer stem cells, leading to cell quiescence and PTEN-mediated inhibition of the PI3K-mTOR pathway, thereby conferring chemoresistance.","method":"SETD4 overexpression in lung cancer cells, H4K20me3 immunostaining, RNA-seq of activated vs. quiescent cells, PI3K-mTOR pathway western blot","journal":"Stem cells international","confidence":"Medium","confidence_rationale":"Tier 2–3 — overexpression with H4K20me3 readout and pathway analysis, single lab","pmids":["37274024"],"is_preprint":false},{"year":2022,"finding":"The lncRNA CBR3-AS1 interacts with the RNA-binding protein PTBP1 to stabilize SETD4 mRNA, increasing SETD4 protein levels and promoting gestational choriocarcinoma cell proliferation; SETD4 is the functional downstream effector of the CBR3-AS1/PTBP1 axis.","method":"RNA binding protein immunoprecipitation (RIP), RNA pulldown, mRNA stability assay, siRNA knockdown, rescue assays","journal":"Disease markers","confidence":"Medium","confidence_rationale":"Tier 2–3 — RIP and RNA pulldown identifying PTBP1-CBR3-AS1-SETD4 mRNA regulatory axis, rescue assay, single lab","pmids":["35655916"],"is_preprint":false},{"year":2025,"finding":"Dormant Setd4+ hepatic cells maintain a silenced metabolic state through H4K20me3-mediated heterochromatin; chromatin remodeling increases accessibility, triggering activation from dormancy to initiate liver regeneration following chronic injury.","method":"Single-molecule FISH, lineage tracing (Setd4CreERT2;Rosa26lsl-tdTomato), targeted cell ablation (Setd4CreERT2;Rosa26DTA), CUT&RUN-seq for H4K20me3, bulk RNA-seq, chromatin accessibility analysis","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vivo methods (lineage tracing, ablation, CUT&RUN-seq, RNA-seq) establishing H4K20me3-chromatin mechanism for quiescence/activation","pmids":["41177404"],"is_preprint":false}],"current_model":"SETD4 is a lysine methyltransferase that catalyzes H4K20me3 (promoting heterochromatin and cell quiescence), H3K4me1/me2 (activating inflammatory gene expression), and H3K27me3 (repressing target genes), and also methylates non-histone substrates including KU70-K570 (suppressing apoptosis) and TBK1-K607 (promoting antiviral interferon signaling), with its nuclear translocation and substrate recruitment regulated by context-specific adaptor proteins such as ZNF268a."},"narrative":{"teleology":[{"year":2013,"claim":"Initial characterization established SETD4 as a dual-compartment (cytosolic/nuclear) lysine methyltransferase whose loss impairs breast cancer cell proliferation and G1/S transition, linking this uncharacterized SET-domain protein to cell cycle control.","evidence":"siRNA knockdown in breast cancer cells with cell fractionation, flow cytometry, and cyclin D1 western blot","pmids":["24738023"],"confidence":"Medium","gaps":["No specific histone or non-histone substrate identified","Single cancer cell line, unclear generalizability","Mechanism connecting SETD4 to cyclin D1 expression undefined"]},{"year":2017,"claim":"The first enzymatic substrate was identified: SETD4 catalyzes H4K20 trimethylation, and this activity is required for heterochromatin-dependent cellular quiescence, establishing SETD4 as an H4K20me3 writer.","evidence":"In vitro HMT assay on histones plus Artemia siRNA knockdown showing H4K20me3 loss and failure to enter diapause quiescence","pmids":["28031330"],"confidence":"High","gaps":["Whether mammalian SETD4 performs the same H4K20me3 reaction in vivo not yet shown","Structural basis for H4K20 specificity unknown"]},{"year":2019,"claim":"SETD4 was shown to possess a second, distinct histone substrate specificity—H3K4me1/me2—and to translocate to the nucleus upon inflammatory stimulation, directly linking its methyltransferase activity to activation of TNF-α and IL-6 transcription in macrophages.","evidence":"SETD4-knockout mouse bone marrow-derived macrophages, in vitro HMT assay, ChIP at TNF-α/IL-6 promoters, immunofluorescence for nuclear translocation","pmids":["31376731"],"confidence":"High","gaps":["Dual substrate specificity (H4K20me3 vs H3K4me1/me2) regulation or context dependence unclear","Mechanism of stimulus-dependent nuclear translocation unresolved"]},{"year":2021,"claim":"Mammalian in vivo studies confirmed that SETD4-mediated H4K20me3 enforces quiescence in both cardiac progenitor cells and neural stem cells, with conditional knockout causing quiescence exit and functional consequences (cardiac repair, neurogenesis), generalizing the quiescence mechanism across tissue-resident stem cells.","evidence":"Conditional knockout mice (c-Kit-CreERT2;Setd4f/f for cardiac; lineage tracing/OE for NSCs), H4K20me3 immunostaining, pathway analysis (PI3K-Akt-mTOR)","pmids":["34079011","36027907"],"confidence":"Medium","gaps":["Direct H4K20me3 ChIP-seq genome-wide targets in mammalian quiescent cells not mapped","Whether PI3K-Akt-mTOR suppression is a direct H4K20me3 target gene effect or indirect remains unclear"]},{"year":2022,"claim":"SETD4 was revealed to methylate the non-histone substrate KU70 at K570, establishing a cytoplasmic function whereby methylated KU70 suppresses apoptosis—the first demonstration that SETD4's cytosolic fraction has a defined substrate and biological role.","evidence":"Co-IP, in vitro methylation assay, site-directed mutagenesis of SETD4 (Y272F/Y284F) and KU70 (K570R), apoptosis readout by flow cytometry","pmids":["35545041"],"confidence":"High","gaps":["Whether KU70 methylation at K570 affects DNA repair function in addition to apoptosis not tested","Structural basis for SETD4 recognizing KU70 vs. histones unknown"]},{"year":2023,"claim":"A second non-histone substrate, TBK1 (K607), was identified, with the adaptor ZNF268a mediating recruitment of SETD4 to TBK1 upon viral infection, establishing a role for SETD4 in innate antiviral interferon signaling and revealing a paradigm for adaptor-dependent substrate selection.","evidence":"Reciprocal co-IP of ZNF268a–SETD4–TBK1, in vitro methylation assay, K607 mutagenesis, IFN signaling reporter and functional readout","pmids":["37926288"],"confidence":"High","gaps":["Full spectrum of adaptor proteins directing SETD4 to other substrates unknown","In vivo antiviral phenotype of SETD4 KO not reported"]},{"year":2023,"claim":"A third histone specificity—H3K27me3 at the NUPR1 promoter—was attributed to SETD4, with repression of NUPR1 inactivating Akt signaling and suppressing prostate cancer tumorigenesis, expanding the catalog of SETD4 histone marks to include a repressive modification beyond H4K20me3.","evidence":"SETD4 knockdown in prostate cancer cells, ChIP for H3K27me3 at NUPR1 promoter, Akt pathway western blot","pmids":["37879429"],"confidence":"Medium","gaps":["In vitro methyltransferase assay for H3K27 not reported; SETD4 could recruit another HMT","Single promoter examined; genome-wide H3K27me3 changes upon SETD4 loss unknown"]},{"year":2025,"claim":"CUT&RUN-seq in hepatic reserve cells demonstrated that H4K20me3 deposited by SETD4 directly silences metabolic gene loci and that chromatin remodeling upon injury releases this silencing to initiate liver regeneration, providing the first genome-wide chromatin map of SETD4-dependent quiescence.","evidence":"Setd4-CreERT2 lineage tracing, targeted ablation, CUT&RUN-seq for H4K20me3, RNA-seq, chromatin accessibility in chronic liver injury models","pmids":["41177404"],"confidence":"High","gaps":["Chromatin remodelers that reverse H4K20me3-mediated silencing not identified","Whether SETD4 is the sole H4K20me3 writer in hepatic dormant cells or acts redundantly with SUV420H1/H2 unresolved"]},{"year":null,"claim":"How SETD4 achieves substrate selectivity across at least three histone marks (H4K20me3, H3K4me1/me2, H3K27me3) and two non-histone substrates in different cellular contexts remains a central unresolved question.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of SETD4 catalytic domain with any substrate","Context-dependent regulatory mechanisms (post-translational modifications, adaptor proteins beyond ZNF268a) largely uncharacterized","Whether multi-substrate specificity reflects direct catalysis in every case or indirect recruitment of other methyltransferases is not fully resolved for H3K27"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,2,5,8]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[1,2,7]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[5,8]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,5]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,2]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[1,3,6,9,11]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,8]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,9]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5]}],"complexes":[],"partners":["KU70","TBK1","ZNF268A","PTBP1"],"other_free_text":[]},"mechanistic_narrative":"SETD4 is a lysine methyltransferase that functions as a central epigenetic regulator of cellular quiescence and inflammatory signaling through methylation of both histone and non-histone substrates. Its principal chromatin-level activity is trimethylation of H4K20 (H4K20me3), which drives heterochromatin formation and enforces quiescence in multiple stem/progenitor cell types including neural stem cells, cardiac progenitor cells, hepatic reserve cells, and cancer stem cells, acting upstream of the PI3K-Akt-mTOR pathway [PMID:28031330, PMID:34079011, PMID:36027907, PMID:41177404]. SETD4 also catalyzes H3K4me1/me2 at inflammatory gene promoters to activate TNF-α and IL-6 transcription in macrophages [PMID:31376731], and H3K27me3 at the NUPR1 promoter to repress prostate cancer tumorigenesis [PMID:37879429]. Beyond histones, SETD4 methylates KU70 at K570 to suppress apoptosis [PMID:35545041] and TBK1 at K607—recruited via the adaptor ZNF268a—to promote antiviral interferon signaling [PMID:37926288]."},"prefetch_data":{"uniprot":{"accession":"Q9NVD3","full_name":"SET domain-containing protein 4","aliases":[],"length_aa":440,"mass_kda":50.4,"function":"Protein-lysine N-methyltransferase that methylates both histones and non-histone proteins (PubMed:31308046, PubMed:35545041, PubMed:37926288). Via its catalytic activity, regulates many processes, including cell proliferation, cell differentiation, inflammatory response and apoptosis. Regulates the inflammatory response by mediating mono- and dimethylation of 'Lys-4' of histone H3 (H3K4me1 and H3K4me2, respectively), leading to activate the transcription of pro-inflammatory cytokines IL6 and TNF (By similarity). Through the catalysis of TBK1 monomethylation, may regulate virus-induced interferon signaling. TBK1 monomethylation enhances its interaction with MAVS, STING and IRF3, hence promoting antiviral interferon signaling (PubMed:37926288). Also involved in the regulation of stem cell quiescence by catalyzing the trimethylation of 'Lys-20' of histone H4 (H4K20me3), thereby promoting heterochromatin formation (PubMed:31308046). In the brain, epigenetically controls quiescence of neural stem cells for sustaining a protected neural stem cell population and maintaining a stem cell reservoir for neurogenesis (By similarity). Involved in proliferation, migration, paracrine and myogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) (By similarity). Through the catalysis of XRCC5/Ku70 trimethylation, regulates BAX-mediated apoptosis. SETD4-catalyzed XRCC5 methylation results in XRCC5 translocation to the cytoplasm, where it interacts with BAX, sequestering it from the mitochondria, hence preventing BAX-mediated apoptosis (PubMed:35545041)","subcellular_location":"Cytoplasm, cytosol; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9NVD3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SETD4","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SETD4","total_profiled":1310},"omim":[{"mim_id":"620995","title":"SET DOMAIN-CONTAINING PROTEIN 4; SETD4","url":"https://www.omim.org/entry/620995"},{"mim_id":"604834","title":"TANK-BINDING KINASE 1; TBK1","url":"https://www.omim.org/entry/604834"},{"mim_id":"604753","title":"ZINC FINGER PROTEIN 268; ZNF268","url":"https://www.omim.org/entry/604753"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nuclear speckles","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SETD4"},"hgnc":{"alias_symbol":[],"prev_symbol":["C21orf27","C21orf18"]},"alphafold":{"accession":"Q9NVD3","domains":[{"cath_id":"3.90.1410.10","chopping":"84-229","consensus_level":"high","plddt":96.1992,"start":84,"end":229},{"cath_id":"-","chopping":"297-439","consensus_level":"high","plddt":93.6262,"start":297,"end":439}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NVD3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NVD3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NVD3-F1-predicted_aligned_error_v6.png","plddt_mean":93.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SETD4","jax_strain_url":"https://www.jax.org/strain/search?query=SETD4"},"sequence":{"accession":"Q9NVD3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NVD3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NVD3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NVD3"}},"corpus_meta":[{"pmid":"24738023","id":"PMC_24738023","title":"SET domain-containing Protein 4 (SETD4) is a Newly Identified Cytosolic and Nuclear Lysine Methyltransferase involved in Breast Cancer Cell Proliferation.","date":"2013","source":"Journal of cancer science & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24738023","citation_count":33,"is_preprint":false},{"pmid":"28031330","id":"PMC_28031330","title":"SETD4 Regulates Cell Quiescence and Catalyzes the Trimethylation of H4K20 during Diapause Formation in Artemia.","date":"2017","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28031330","citation_count":32,"is_preprint":false},{"pmid":"31376731","id":"PMC_31376731","title":"The novel methyltransferase SETD4 regulates TLR agonist-induced expression of cytokines through methylation of lysine 4 at histone 3 in macrophages.","date":"2019","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31376731","citation_count":25,"is_preprint":false},{"pmid":"37879429","id":"PMC_37879429","title":"SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrest.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37879429","citation_count":13,"is_preprint":false},{"pmid":"34079011","id":"PMC_34079011","title":"Setd4 controlled quiescent c-Kit+ cells contribute to cardiac neovascularization of capillaries beyond activation.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34079011","citation_count":13,"is_preprint":false},{"pmid":"33506343","id":"PMC_33506343","title":"SETD4 in the Proliferation, Migration, Angiogenesis, Myogenic Differentiation and Genomic Methylation of Bone Marrow Mesenchymal Stem Cells.","date":"2021","source":"Stem cell reviews and reports","url":"https://pubmed.ncbi.nlm.nih.gov/33506343","citation_count":12,"is_preprint":false},{"pmid":"35545041","id":"PMC_35545041","title":"SETD4-mediated KU70 methylation suppresses apoptosis.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35545041","citation_count":10,"is_preprint":false},{"pmid":"34131249","id":"PMC_34131249","title":"SETD4-expressing cells contribute to pancreatic development and response to cerulein induced pancreatitis injury.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34131249","citation_count":7,"is_preprint":false},{"pmid":"36027907","id":"PMC_36027907","title":"SETD4 cells contribute to brain development and maintain adult stem cell reservoir for neurogenesis.","date":"2022","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36027907","citation_count":6,"is_preprint":false},{"pmid":"37274024","id":"PMC_37274024","title":"SETD4 Confers Cancer Stem Cell Chemoresistance in Nonsmall Cell Lung Cancer Patients via the Epigenetic Regulation of Cellular Quiescence.","date":"2023","source":"Stem cells international","url":"https://pubmed.ncbi.nlm.nih.gov/37274024","citation_count":6,"is_preprint":false},{"pmid":"31794893","id":"PMC_31794893","title":"Loss of Setd4 delays radiation-induced thymic lymphoma in mice.","date":"2019","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/31794893","citation_count":6,"is_preprint":false},{"pmid":"35655916","id":"PMC_35655916","title":"CBR3-AS1 Accelerates the Malignant Proliferation of Gestational Choriocarcinoma Cells by Stabilizing SETD4.","date":"2022","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/35655916","citation_count":6,"is_preprint":false},{"pmid":"37926288","id":"PMC_37926288","title":"TBK1-stabilized ZNF268a recruits SETD4 to methylate TBK1 for efficient interferon signaling.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37926288","citation_count":4,"is_preprint":false},{"pmid":"39817582","id":"PMC_39817582","title":"Identification of SETD4 as an Onco-Immunological Biomarker Encompassing the Tumor Microenvironment, Prognoses, and Therapeutic Responses in Various Human Cancers.","date":"2025","source":"Immunity, inflammation and disease","url":"https://pubmed.ncbi.nlm.nih.gov/39817582","citation_count":1,"is_preprint":false},{"pmid":"41947902","id":"PMC_41947902","title":"SETD4 as a marker of disease burden and treatment response in childhood acute lymphoblastic leukemiaSETD4 as a marker of disease burden and treatment response in childhood acute lymphoblastic leukemia.","date":"2026","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/41947902","citation_count":0,"is_preprint":false},{"pmid":"41177404","id":"PMC_41177404","title":"Setd4-expressing cells drive regenerative recovery in chronic liver injury.","date":"2025","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/41177404","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9706,"output_tokens":2993,"usd":0.037006},"stage2":{"model":"claude-opus-4-6","input_tokens":6366,"output_tokens":2659,"usd":0.147457},"total_usd":0.184463,"stage1_batch_id":"msgbatch_011rkcQdVV1RaFq9XhcG6df6","stage2_batch_id":"msgbatch_01RzgrJafdF4EWHhj5mNi6dh","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"SETD4 is a lysine methyltransferase that localizes to both the cytosol and nucleus in breast cancer cells, and its knockdown suppresses proliferation, delays G1/S cell cycle transition, and decreases cyclin D1 expression without affecting apoptosis.\",\n      \"method\": \"Cell fractionation, confocal immunofluorescence, siRNA knockdown, western blot, flow cytometry\",\n      \"journal\": \"Journal of cancer science & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — clean KD with defined cellular phenotype and molecular readout (cyclin D1), single lab\",\n      \"pmids\": [\"24738023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SETD4 (Ar-SETD4) catalyzes trimethylation of histone H4K20 (H4K20me3) to promote cell quiescence; knockdown of Ar-SETD4 significantly reduces H4K20me3 levels and prevents quiescent diapause embryo formation in Artemia.\",\n      \"method\": \"In vitro histone methyltransferase (HMT) assay, overexpression in cell lines, siRNA knockdown, western blot\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro HMT assay confirming enzymatic activity on H4K20, complemented by in vivo knockdown with phenotypic readout\",\n      \"pmids\": [\"28031330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SETD4 translocates from the cytosol to the nucleus upon LPS stimulation and catalyzes H3K4 monomethylation and dimethylation (H3K4me1/me2) at the TNF-α and IL-6 promoters, thereby positively regulating inflammatory cytokine expression in macrophages downstream of MAPK and NF-κB pathways.\",\n      \"method\": \"In vitro HMTase assay, SETD4-/- mouse BMDMs, RNA interference, ChIP (H3K4me1/me2 at promoters), immunofluorescence for nuclear translocation\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro HMT assay plus KO macrophages plus ChIP at target gene promoters, multiple orthogonal methods\",\n      \"pmids\": [\"31376731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Setd4 regulates quiescence of c-Kit+ cardiac progenitor cells via H4K20me3-mediated heterochromatin formation and through the PI3K-Akt-mTOR signaling pathway; conditional knockout of Setd4 causes quiescence exit, increased capillary endothelial cells, and improved cardiac function after myocardial infarction.\",\n      \"method\": \"Conditional knockout (c-Kit-CreERT2;Setd4f/f mice), lineage tracing (Setd4-Cre;Rosa26mT/mG), immunostaining for H4K20me3, pathway analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined cellular and molecular phenotype in vivo, single lab\",\n      \"pmids\": [\"34079011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SETD4 knockout in bone marrow mesenchymal stem cells inhibits histone lysine monomethylases and dimethylases and alters genomic DNA methylation at 96,331 CpG sites (affecting promoter regions of genes involved in stem cell biology), impairs migration, myogenic differentiation, and angiogenesis via paracrine VEGF.\",\n      \"method\": \"CRISPR/Cas9 KO mice, Reduced Representation Bisulfite Sequencing (RRBS), western blot, functional assays (migration, differentiation, angiogenesis)\",\n      \"journal\": \"Stem cell reviews and reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — CRISPR KO with genome-wide methylation sequencing and functional phenotypes, single lab\",\n      \"pmids\": [\"33506343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SETD4 methylates the non-histone protein KU70 at lysine 570 (K570); mutations Y272F and Y284F in SETD4 abolish this methylation. Methylated KU70 is enriched in the cytoplasm and suppresses staurosporine-induced apoptosis; the KU70-K570R mutation dampens this anti-apoptotic activity.\",\n      \"method\": \"Co-IP, in vitro methylation assay, site-directed mutagenesis (SETD4-Y272/284F; KU70-K570R), overexpression/knockdown with apoptosis readout (flow cytometry, cell viability)\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro methylation assay plus mutagenesis of both enzyme and substrate, functional apoptosis readout, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"35545041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SETD4 epigenetically regulates neural stem cell (NSC) quiescence via H4K20me3-mediated heterochromatin; conditional knockout of Setd4 causes quiescence exit and increased neurogenesis, while overexpression causes quiescence entry and suppressed neurogenesis, demonstrating SETD4 as an epigenetic determinant of deep NSC quiescence.\",\n      \"method\": \"Conditional knockout, lineage tracing, immunostaining for H4K20me3, overexpression in mice\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic KO/OE with defined molecular and phenotypic readouts, single lab\",\n      \"pmids\": [\"36027907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SETD4 methylates H3K27 to generate H3K27me3 at the NUPR1 promoter, repressing NUPR1 transcription, which subsequently inactivates the Akt signaling pathway and impedes prostate cancer tumorigenesis.\",\n      \"method\": \"SETD4 knockdown in PCa cells, ChIP for H3K27me3 at NUPR1 promoter, western blot for Akt pathway components\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — KD plus ChIP demonstrating H3K27me3 at specific promoter with downstream pathway readout, single lab\",\n      \"pmids\": [\"37879429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Upon viral infection, TBK1-stabilized ZNF268a recruits SETD4 to TBK1, which then catalyzes mono-methylation of TBK1 at lysine 607, critical for assembly of the TBK1 signaling complex and efficient antiviral interferon signaling.\",\n      \"method\": \"Co-IP (ZNF268a–SETD4–TBK1 interactions), in vitro methylation assay, site-directed mutagenesis, overexpression/knockdown with IFN signaling readout\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro methylation assay identifying TBK1-K607 as substrate, reciprocal co-IP, mutagenesis, functional IFN signaling readout\",\n      \"pmids\": [\"37926288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SETD4 promotes H4K20me3-mediated heterochromatin formation in quiescent lung cancer stem cells, leading to cell quiescence and PTEN-mediated inhibition of the PI3K-mTOR pathway, thereby conferring chemoresistance.\",\n      \"method\": \"SETD4 overexpression in lung cancer cells, H4K20me3 immunostaining, RNA-seq of activated vs. quiescent cells, PI3K-mTOR pathway western blot\",\n      \"journal\": \"Stem cells international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — overexpression with H4K20me3 readout and pathway analysis, single lab\",\n      \"pmids\": [\"37274024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The lncRNA CBR3-AS1 interacts with the RNA-binding protein PTBP1 to stabilize SETD4 mRNA, increasing SETD4 protein levels and promoting gestational choriocarcinoma cell proliferation; SETD4 is the functional downstream effector of the CBR3-AS1/PTBP1 axis.\",\n      \"method\": \"RNA binding protein immunoprecipitation (RIP), RNA pulldown, mRNA stability assay, siRNA knockdown, rescue assays\",\n      \"journal\": \"Disease markers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — RIP and RNA pulldown identifying PTBP1-CBR3-AS1-SETD4 mRNA regulatory axis, rescue assay, single lab\",\n      \"pmids\": [\"35655916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Dormant Setd4+ hepatic cells maintain a silenced metabolic state through H4K20me3-mediated heterochromatin; chromatin remodeling increases accessibility, triggering activation from dormancy to initiate liver regeneration following chronic injury.\",\n      \"method\": \"Single-molecule FISH, lineage tracing (Setd4CreERT2;Rosa26lsl-tdTomato), targeted cell ablation (Setd4CreERT2;Rosa26DTA), CUT&RUN-seq for H4K20me3, bulk RNA-seq, chromatin accessibility analysis\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vivo methods (lineage tracing, ablation, CUT&RUN-seq, RNA-seq) establishing H4K20me3-chromatin mechanism for quiescence/activation\",\n      \"pmids\": [\"41177404\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SETD4 is a lysine methyltransferase that catalyzes H4K20me3 (promoting heterochromatin and cell quiescence), H3K4me1/me2 (activating inflammatory gene expression), and H3K27me3 (repressing target genes), and also methylates non-histone substrates including KU70-K570 (suppressing apoptosis) and TBK1-K607 (promoting antiviral interferon signaling), with its nuclear translocation and substrate recruitment regulated by context-specific adaptor proteins such as ZNF268a.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SETD4 is a lysine methyltransferase that functions as a central epigenetic regulator of cellular quiescence and inflammatory signaling through methylation of both histone and non-histone substrates. Its principal chromatin-level activity is trimethylation of H4K20 (H4K20me3), which drives heterochromatin formation and enforces quiescence in multiple stem/progenitor cell types including neural stem cells, cardiac progenitor cells, hepatic reserve cells, and cancer stem cells, acting upstream of the PI3K-Akt-mTOR pathway [PMID:28031330, PMID:34079011, PMID:36027907, PMID:41177404]. SETD4 also catalyzes H3K4me1/me2 at inflammatory gene promoters to activate TNF-α and IL-6 transcription in macrophages [PMID:31376731], and H3K27me3 at the NUPR1 promoter to repress prostate cancer tumorigenesis [PMID:37879429]. Beyond histones, SETD4 methylates KU70 at K570 to suppress apoptosis [PMID:35545041] and TBK1 at K607—recruited via the adaptor ZNF268a—to promote antiviral interferon signaling [PMID:37926288].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Initial characterization established SETD4 as a dual-compartment (cytosolic/nuclear) lysine methyltransferase whose loss impairs breast cancer cell proliferation and G1/S transition, linking this uncharacterized SET-domain protein to cell cycle control.\",\n      \"evidence\": \"siRNA knockdown in breast cancer cells with cell fractionation, flow cytometry, and cyclin D1 western blot\",\n      \"pmids\": [\"24738023\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No specific histone or non-histone substrate identified\", \"Single cancer cell line, unclear generalizability\", \"Mechanism connecting SETD4 to cyclin D1 expression undefined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The first enzymatic substrate was identified: SETD4 catalyzes H4K20 trimethylation, and this activity is required for heterochromatin-dependent cellular quiescence, establishing SETD4 as an H4K20me3 writer.\",\n      \"evidence\": \"In vitro HMT assay on histones plus Artemia siRNA knockdown showing H4K20me3 loss and failure to enter diapause quiescence\",\n      \"pmids\": [\"28031330\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether mammalian SETD4 performs the same H4K20me3 reaction in vivo not yet shown\", \"Structural basis for H4K20 specificity unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"SETD4 was shown to possess a second, distinct histone substrate specificity—H3K4me1/me2—and to translocate to the nucleus upon inflammatory stimulation, directly linking its methyltransferase activity to activation of TNF-α and IL-6 transcription in macrophages.\",\n      \"evidence\": \"SETD4-knockout mouse bone marrow-derived macrophages, in vitro HMT assay, ChIP at TNF-α/IL-6 promoters, immunofluorescence for nuclear translocation\",\n      \"pmids\": [\"31376731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dual substrate specificity (H4K20me3 vs H3K4me1/me2) regulation or context dependence unclear\", \"Mechanism of stimulus-dependent nuclear translocation unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mammalian in vivo studies confirmed that SETD4-mediated H4K20me3 enforces quiescence in both cardiac progenitor cells and neural stem cells, with conditional knockout causing quiescence exit and functional consequences (cardiac repair, neurogenesis), generalizing the quiescence mechanism across tissue-resident stem cells.\",\n      \"evidence\": \"Conditional knockout mice (c-Kit-CreERT2;Setd4f/f for cardiac; lineage tracing/OE for NSCs), H4K20me3 immunostaining, pathway analysis (PI3K-Akt-mTOR)\",\n      \"pmids\": [\"34079011\", \"36027907\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct H4K20me3 ChIP-seq genome-wide targets in mammalian quiescent cells not mapped\", \"Whether PI3K-Akt-mTOR suppression is a direct H4K20me3 target gene effect or indirect remains unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"SETD4 was revealed to methylate the non-histone substrate KU70 at K570, establishing a cytoplasmic function whereby methylated KU70 suppresses apoptosis—the first demonstration that SETD4's cytosolic fraction has a defined substrate and biological role.\",\n      \"evidence\": \"Co-IP, in vitro methylation assay, site-directed mutagenesis of SETD4 (Y272F/Y284F) and KU70 (K570R), apoptosis readout by flow cytometry\",\n      \"pmids\": [\"35545041\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether KU70 methylation at K570 affects DNA repair function in addition to apoptosis not tested\", \"Structural basis for SETD4 recognizing KU70 vs. histones unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A second non-histone substrate, TBK1 (K607), was identified, with the adaptor ZNF268a mediating recruitment of SETD4 to TBK1 upon viral infection, establishing a role for SETD4 in innate antiviral interferon signaling and revealing a paradigm for adaptor-dependent substrate selection.\",\n      \"evidence\": \"Reciprocal co-IP of ZNF268a–SETD4–TBK1, in vitro methylation assay, K607 mutagenesis, IFN signaling reporter and functional readout\",\n      \"pmids\": [\"37926288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full spectrum of adaptor proteins directing SETD4 to other substrates unknown\", \"In vivo antiviral phenotype of SETD4 KO not reported\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A third histone specificity—H3K27me3 at the NUPR1 promoter—was attributed to SETD4, with repression of NUPR1 inactivating Akt signaling and suppressing prostate cancer tumorigenesis, expanding the catalog of SETD4 histone marks to include a repressive modification beyond H4K20me3.\",\n      \"evidence\": \"SETD4 knockdown in prostate cancer cells, ChIP for H3K27me3 at NUPR1 promoter, Akt pathway western blot\",\n      \"pmids\": [\"37879429\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro methyltransferase assay for H3K27 not reported; SETD4 could recruit another HMT\", \"Single promoter examined; genome-wide H3K27me3 changes upon SETD4 loss unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"CUT&RUN-seq in hepatic reserve cells demonstrated that H4K20me3 deposited by SETD4 directly silences metabolic gene loci and that chromatin remodeling upon injury releases this silencing to initiate liver regeneration, providing the first genome-wide chromatin map of SETD4-dependent quiescence.\",\n      \"evidence\": \"Setd4-CreERT2 lineage tracing, targeted ablation, CUT&RUN-seq for H4K20me3, RNA-seq, chromatin accessibility in chronic liver injury models\",\n      \"pmids\": [\"41177404\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin remodelers that reverse H4K20me3-mediated silencing not identified\", \"Whether SETD4 is the sole H4K20me3 writer in hepatic dormant cells or acts redundantly with SUV420H1/H2 unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SETD4 achieves substrate selectivity across at least three histone marks (H4K20me3, H3K4me1/me2, H3K27me3) and two non-histone substrates in different cellular contexts remains a central unresolved question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of SETD4 catalytic domain with any substrate\", \"Context-dependent regulatory mechanisms (post-translational modifications, adaptor proteins beyond ZNF268a) largely uncharacterized\", \"Whether multi-substrate specificity reflects direct catalysis in every case or indirect recruitment of other methyltransferases is not fully resolved for H3K27\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 2, 5, 8]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [1, 2, 7]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [5, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [1, 3, 6, 9, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 8]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 9]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"KU70\", \"TBK1\", \"ZNF268a\", \"PTBP1\"],\n    \"other_free_text\": []\n  }\n}\n```"}